News

Examining Milestone Pharmaceuticals' Progress Towards FDA Approval

Examining Milestone Pharmaceuticals' Progress Towards FDA Approval

Milestone Pharmaceuticals Updates on Financial Results

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) recently provided a detailed overview of its fourth-quarter and full-year financial outcomes, alongside pivotal updates regarding its regulatory processes and operational strategies. The company is gearing up for the potential FDA approval of CARDAMYST™, a nasal spray designed for the treatment of paroxysmal supraventricular tachycardia (PSVT).

Financial Overview from Q4 2024

As of the end of December 2024, Milestone reported cash, cash equivalents, and short-term investments amounting to $69.7 million. This is a slight increase from $66.0 million recorded a year prior. Importantly, the company has indicated no revenue generation during the fourth quarter or throughout 2024, contrasting with the $1.0 million milestone payment received in 2023 from Corxel Pharmaceuticals.

Research and Development Efforts

For the fourth quarter of 2024, research and development expenses totaled $3.9 million, a significant reduction from the $5.5 million spent in the same period the previous year. Overall, for the full year 2024, total R&D costs were $14.4 million compared to $31.1 million in 2023. This significant decrease reflects the completion of several clinical studies. Meanwhile, general and administrative expenses rose modestly to $4.0 million from $3.4 million year-over-year, with full-year expenses reaching $16.7 million.

Regulatory Updates on CARDAMYST

Milestone is advancing towards obtaining FDA approval for CARDAMYST, its investigational nasal spray for PSVT. As part of this effort, the FDA accepted the New Drug Application (NDA) in May 2024, assigning a Prescription Drug User Fee Act (PDUFA) review goal date of March 27, 2025. If approved, the launch of CARDAMYST is anticipated mid-2025, positioning Milestone to provide a vital new treatment option.

Commercial Strategies and Patents

Milestone has taken proactive steps in preparing for the potential launch, including hosting a Commercial Launch Plan investor event. This event provided insights into their strategies for promoting CARDAMYST, ensuring that healthcare providers and patients have access upon approval. Adding to their positive outlook, Milestone has received a Notice of Allowance for a new method-of-use patent covering the etripamil nasal spray, which could extend intellectual property protection until July 2042.

Etripamil Development for AFib-RVR

In addition to its PSVT focus, Milestone plans to initiate a Phase 3 trial for etripamil in patients with atrial fibrillation rapid ventricular response (AFib-RVR) in 2025. The clinical trial aims to evaluate self-administration of the etripamil nasal spray, which can empower patients by enabling them to manage episodes without immediate medical oversight.

Future Outlook and Investor Relations

Milestone Pharmaceuticals remains firmly positioned to commercialize CARDAMYST, pending FDA approval, supported by a solid financial foundation and a strategic commercialization framework. The management team, led by President and CEO Joseph Oliveto, expressed confidence in their preparations for the launch and in the product’s potential to address the needs of patients suffering from PSVT.

Contact Information

For more details on Milestone's financial performance and future outlook, please reach out to:

Kim Fox
Vice President, Communications
kfox@milestonepharma.com

Kevin Gardner
Investor Relations
kgardner@lifesciadvisors.com

Frequently Asked Questions

What is CARDAMYST?

CARDAMYST is Milestone Pharmaceuticals' investigational nasal spray designed for the treatment of paroxysmal supraventricular tachycardia (PSVT).

What are the financial results for Milestone Pharmaceuticals in Q4 2024?

Milestone reported cash reserves of $69.7 million and no revenue generated during the fourth quarter of 2024.

What is the expected launch date for CARDAMYST?

If FDA approval is granted, CARDAMYST is expected to launch in mid-2025.

How does Milestone plan to commercialize CARDAMYST?

Milestone has devised a strategic commercial launch plan, including investor events to discuss their marketing strategies.

Who can I contact for more information regarding Milestone Pharmaceuticals?

You can reach out to Kim Fox, VP of Communications, or Kevin Gardner for investor-related inquiries through the provided email addresses.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Liberty Hill: 50 Years of Grassroots Revolution

Updated Category News Views 4

Half a Century of Community Empowerment You don't see organizations sticking to their guns for fifty years without having something real to offer. Liberty Hill Foundation is celebrating this colossal milestone in style by throwing their weight behind 17 grassroots groups under the 2026 Fund for Change. They're not just tossing money around but are genuinely becoming the...

Continue Reading
Bitwise Pulls Plug on Dogecoin ETF Amid Market Risks

Updated Category News Views 6

Bitwise Ditches Dogecoin ETF: End of a Speculative Era Who knew that a digital asset inspired by an internet meme would get a platform on Wall Street? Well, Bitwise did. They rallied behind Dogecoin, launching the Bitwise Dogecoin ETF, ticker BWOW. But as of September 10, 2026, the fund's journey is coming to an end with liquidation just around the corner. What Sparked...

Continue Reading
Red-Eye Flights Surge, Driven By Western U.S. Routes

Updated Category News Views 5

You can always count on some things staying the same, right? Well, if you thought red-eye flights were going to fade away, think again. These late-night wonders are not just hanging around—they're booming in the west like there's no tomorrow. Literally. Champion Traveler has laid it all out for us: about 115,580 overnight flights in 2025, a record high since this mad...

Continue Reading
Rare Collectibles Highlight Morphy's Auction on Oct 4

Updated Category News Views 2

Anticipation Builds for Morphy's Auction Event Morphy's upcoming event on October 4th is all about tapping into the era of revved engines, gleaming gasoline signs, and some history that could put Hollywood tales to shame. The auction isn't just a stroll down memory lane; it features over 650 lots, each a time capsule of America's automotive past. From Al Capone's ritzy...

Continue Reading
AbbVie's Bold Leap in Menstrual Migraine Treatment

Updated Category News Views 10

AbbVie's Game-Changing Atogepant Study When it comes to pushing boundaries in the pharmaceutical world, there's no sitting on the fence. AbbVie's Phase 3 LUNA study results are painting a bright picture for women who suffer from the relentless grip of menstrual migraines. In a world where not a single treatment option has been approved specifically for this condition,...

Continue Reading
Veteran Marketer Joins The Wisory's Advisory Board

Updated Category News Views 3

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Continue Reading
Seismic Pharma Kicks Off Phase 3 Trial for Istaroxime

Updated Category News Views 3

Seismic Sets the Stage for a Medical Milestone From the heart of biotech in Durham, North Carolina, seismic waves ripple through the medical community as Seismic Pharmaceuticals embarks on a high-stakes adventure. It's official: they've enrolled their very first patient in the global Phase 3 trial of istaroxime, targeting the grim specter known as cardiogenic shock. You...

Continue Reading
XKL Delivers MediaLight for High-Speed Optical Transport

Updated Category News Views 2

Unpacking the MediaLight Launch Kicking off September, XKL is tossing its hat in the ring with the MediaLight Xponder and Muxponder systems. These aren't just any run-of-the-mill gizmos—nope, they're touted as top-of-the-line optical transport solutions. The talk of the town is their ability to dish out high-density 100G and 400G transport, and for geeks in the trade,...

Continue Reading
CrossCountry Mortgage Boosts Loan Limits, Flexibility for 2027

Updated Category News Views 13

Trailblazing in the Mortgage Game Well, what do we have here? CrossCountry Mortgage, the big cheese of retail mortgage lenders, is cranking up their conforming loan limits to a hefty $845,000. They're jumping the gun on the Federal Housing Finance Agency's official 2027 announcement. It's a classic move—proactive, bold, and a bit of a gamble, if you ask me. They’re...

Continue Reading
Flex Dental Solutions Adds BNPL, Surcharging to FlexPayments

Updated Category News Views 5

Diving into Dental Finances: A New Moneymaker? It's about time someone shook up the dental payment scene, and Flex Dental Solutions seems to be the one doing it. They rolled out some intriguing new features for their FlexPayments platform aimed squarely at dental practices using Open Dental. What we're seeing here is their attempt to bridge a couple of financial headaches...

Continue Reading

Top 5 Most Recently Viewed Articles

Meiji Seika Pharma Expands KOSTAIVE® Manufacturing In Japan

Updated Category News Views 394

Meiji Seika Pharma Enhances Manufacturing Capabilities Meiji Seika Pharma Co., Ltd., known for its commitment to healthcare, has recently received exciting approval to expand its manufacturing and marketing capabilities for the innovative self-amplifying mRNA vaccine, KOSTAIVE®. This decision marks a significant milestone for the company as it strengthens the local...

Continue Reading
OS Therapies Achieves Milestone in Osteosarcoma Treatment

Updated Category News Views 246

An Exciting Breakthrough in Osteosarcoma Treatment OS Therapies, Inc. (NYSE-A: OSTX), a pioneering biotechnology firm, has recently made waves in the oncology field by completing a Phase 2b clinical trial concerning its innovative treatment, OST-HER2. This trial aims to address the severe challenges faced by patients suffering from lung metastatic osteosarcoma - a rare...

Continue Reading
CEO Andy Byron Takes Leave Following Coldplay Concert Incident

Updated Category News Views 381

CEO Andy Byron Takes Leave Amidst Viral Coldplay Incident Astronomer CEO Andy Byron is currently on leave due to a controversial situation that unfolded during a Coldplay concert. A video that circulated online appears to show Byron embracing the company’s HR head, Kristin Cabot, which ignited a social media frenzy. The Viral Video's Impact The footage, which originated...

Continue Reading
Misunderstood Whiskey's Exciting Launch of Orange Blossom Bourbon

Updated Category News Views 234

Misunderstood Whiskey Launches Orange Blossom Bourbon Misunderstood Whiskey Co. has announced the launch of their eagerly awaited Orange Blossom Bourbon. This marks a significant milestone as it is the brand's first bourbon since it began in 2017. With this release, the company aims to revolutionize the flavored whiskey market by providing high-quality, infused options...

Continue Reading
Impact of Capital Flows on Emerging Markets: A Cautionary Analysis

Updated Category News Views 352

Capital Flow Challenges for Emerging Economies The dynamics of capital flows have become a significant topic of discussion lately, with emerging markets facing potential hurdles that could alter their financial landscape dramatically. Recent insights from JPMorgan, an influential investment bank, shed light on these pressing issues. As economic policies shift globally,...

Continue Reading